Speakers

Discussion of the latest developments in the emerging field of Polymer Therapeutics.

PLENARY SPEAKERS

Anand Subramony Vice President of External innovation and Novel Technologies at AstraZeneca

Anand Subramony is Vice President of External innovation and Novel Technologies at AstraZeneca. In this role, he leads various cross functional teams and initiatives in the areas of nanomedicine, targeted delivery, new modalities/ tech platforms, antibody drug conjugates and lab automation technologies.

Maria Kavallaris Theme Head, Translational Cancer NanoMedicine, and Group Leader of Tumour Biology and Targeting Group, Children’s Cancer Institute, Sydney, Australia

Professor Kavallaris is an interdisciplinary researcher who is advancing cancer nanomedicine. Her discoveries have led to patents, and industry and clinical linkages for the development of cancer therapeutics and devices.

Mustafa Diken Deputy Director Immunotherapy Development Center at Translational Oncology Institute

Dr. Mustafa Diken received his Ph.D. in tumor immunology from Johannes Gutenberg University under the supervision of Prof. Ugur Sahin and is currently serving as Deputy Director Immunotherapy Development Center at Translational Oncology Institute (TRON) as well as Vice President Vaccines & Immunology at BioNTech.

CONFIRMED INVITED SPEAKERS

Gianfranco Pasut Full Professor of Pharmaceutical Technology, Department of Pharmaceutical & Pharmacological Sciences – University of Padova.

Gianfranco Pasut is an expert in PEGylation and drug delivery, presently involved in studying ADCs, targeted liposomes and protein conjugates.

Daniel Gonzalez-Carter Senior Scientist/Junior leader research fellow

Daniel Gonzalez-Carter is interested in designing strategies to deliver nanoparticles across the blood-brain barrier to treat neurodegenerative diseases.

Susan Napier Thomas Woodruff Associate Professor at the Georgia Institute of Technology

Susan Napier Thomas is a Woodruff Associate Professor with tenure at the Georgia Institute of Technology developing immunotherapeutic drug delivery systems.

Cristianne Rijcken Founder and CSO Cristal Therapeutics

Cristianne is founder and CSO of Cristal Therapeutics, which is developing truly enabling technologies including nanomedicine and conjugation technologies

Helena F. Florindo Associate Professor with habilitation; University of Lisbon, Faculty of Pharmacy

Helena Florindo has a PhD in Pharmaceutics, and her research is focused on the development of nano-immunotherapies for cancer treatment.

Marisol Quintero CEO. Highlight Therapeutics

Marisol Quintero runs a biopharmaceutical company based in Spain, and dedicated to the research and development of new treatments in the field of oncology

Daniel Siegwart Associate Professor with habilitation; University of Lisbon, Faculty of Pharmacy

Co-director of the SCCC Chemistry & Cancer Program CPRIT Scholar in Cancer Research

Ann-Christin Pöppler Jun.-Prof. of Organic Structural Chemistry/Institute of Organic Chemistry/University of Wuerzbur

My long-term research interest is the development of new, improved analytical approaches in the context of drug delivery. I aim to achieve this through detailed molecular level understanding and identification of essential structure-property relations combining NMR spectroscopy with synthesis and a variety of complementary analytical methods.

Maria Blanco Prieto University of Navarra (Full Professor)

Maria Blanco-Prieto received her Pharmacy Degree from the University of Santiago de Compostela (Spain), followed by a PhD in Pharmaceutical Sciences from the University of Paris-Sud (France). She completed a post-doctoral training at the Swiss Federal Institute of Technology (ETH), Zürich, (Switzerland) and then joined the University of Navarra where presently she is Full Professor of Pharmacy and Pharmaceutical Technology.

Gloria García Palacios GRA EU Region - Specialty Care – Head I&I and Dupilumab Global Regulatory Affairs

Gloria graduated in Pharmacy from the University Complutense de Madrid (Spain) and has a post-graduate degree in “International Development and Registration of Medicinal Products” from the University of Paris Sud (XI)

Matthias Barz Full Professor for Biotherapeutic Delivery Leiden Academic Center for Drug Research (LACDR)

Dr. Matthias Barz has published more than 100 research papers, commentaries, reviews, book chapters and patents. For his independent research he received numerous awards, including the prestigious Chemie Dozentenpreis (FCI), the Hermann Schnell Scholarship (GDCH) and was named ACS PMSE Young Investigator in 2018.

Satoshi Uchida Associate Professor Medical Chemistry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine

Satoshi Uchida is interested in developing systems for mRNA delivery and vaccines by engineering polymers and mRNA for therapeutic applications.

Lutz Nuhn Emmy Noether Research Group Leader, Max Planck Institute for Polymer Research, Mainz

Lutz Nuhn is head of the Macromolecular (Immuno-)Therapeutics Lab at the MPI-P and wants to design and explore novel degradable polymeric drug delivery systems for vaccination and anti-cancer immunotherapies.”

Ronit Satchi-Fainaro Head, Cancer Research and Nanomedicine Laboratory | Kurt and Herman Lion Chair in Nanosciences and Nanotechnologies | Director, Cancer Biology Research Center, Tel Aviv University

Prof. Ronit Satchi-Fainaro (Ph.D.) is a Full Professor at Tel Aviv University, where she is head of the Cancer Research & Nanomedicine Laboratory, Director of Tel Aviv University and its 17-affiliated hospitals’ Cancer Biology Research Center, Director of the TAU Kahn 3D BioPrinting Initiative, and holds the Lion Chair in Nanosciences and Nanotechnologies.

Fabian Kiessling Chair of Experimental Molecular Imaging University of Aachen (RWTH)

Since 2008 Professor Dr. Fabian Kiessling is leading the Institute of Experimental Molecular Imaging at the Helmholtz Institute for Biomedical Engineering at the RWTH-University in Aachen.

Adam Gormley Assistant Professor of Biomedical Engineering at Rutgers University

Adam Gormley is an Assistant Professor of Biomedical Engineering at Rutgers University and an expert in nanobiomaterials.

Robert Luxenhofer Professor for Soft Matter Chemistry, Department of Chemistry, University of Helsinki

Leading the Soft Matter Chemistry at the University of Helsinki, my main interests are design of novel building blocks for polymer therapeutics and biofabrication.

Christopher Eggers Senior Research Scientist at Promega

Dr. Christopher Eggers received his Ph.D. in biochemistry and molecular biology from the University of California at San Francisco and then completed a postdoctoral fellowship at the Howard Hughes Medical Institute at UC San Diego.

Michael Bevilacqua Co-founder, CEO, & CSO of Amicrobe, Inc.

Dr. Michael P. Bevilacqua has more than 35 years’ experience as a medical scientist, inventor, and executive.

Anthony T.Cheung Engene, CA

Dr. Cheung is the founder and Chief Technology Officer of enGene, a private biotechnology company headquartered in Montreal, Canada.

Mohammed Olusegun Balogun CSIR, South Africa

Principal scientist at the Center for Nanostructures and Advanced Materials, CSIR, SouthAfrica

Roey J. Amir Academic Head of the ADAMA Center for Novel Delivery Systems in Crop Protection

Academic Head of the ADAMA Center for Novel Delivery Systems in Crop Protection Academic Head of the Medicinal Chemistry Unit in The Blavatnik Center for Drug Discovery

Sébastien Rouzeau Product Manager GPC/SEC Systems in TOSOH BIOSCIENCE

Sébastien holds a Ph.D. in Polymer Science from the National Institute of Applied Science in Lyon, France.

Eric Allémann Co-founder of KYLYS

Eric is co-founder of KYLYS, a biotech start-up company. He is committee member of the Société académique de Genève, committee member of UNITEC, the TTO of University of Geneva, president of the Institute of translational molecular imaging Foundation (Geneva), president of the Mark Birkigt fund.

Ralf Kraehmer Managing Director and Founder celares GmbH

Managing Director and Founder celares GmbH

Warren Chan Professor of Nanobioengineering, and the Director of the Institute of Biomedical Engineering at the Univ. of Toronto

Professor Warren Chan joined the University of Toronto’s Institute of Biomaterials & Biomedical Engineering (IBBME) in 2002, was promoted to associate professor in 2008 and to full professor in 2012.

Peter L. Turecek Hon.Prof (FH) Univ.-Doz. Dr. Senior Director

Hon.Prof (FH) Univ.-Doz. Dr. Senior Director

Khaled Greish Professor of Molecular Medicine, and head of the Nano-research unit, at Princes Al-Jawhara Center, Arabian Gulf University, Kingdom of Bahrain

Dr. Khaled Greish is Professor of Molecular Medicine, and head of the Nano-research unit, at Princes Al-Jawhara Center, Arabian Gulf University, Kingdom of Bahrain.

Cameron Alexander Professor of Polymer Therapeutics at the School of Pharmacy, University of Nottingham, UK

Professor Alexander received degrees (BSc and PhD) in Chemistry from the University of Durham, UK and carried out post-doctoral research at the Melville Laboratory for Polymer Synthesis, University of Cambridge. He is a Fellow of the Royal Society of Chemistry and received the UK Macro Group Medal in 2014 for contributions to polymer science.

Ruth Schmid Vice President Marketing at SINTEF Industry in Trondheim

Her present research activities include the preparation and characterisation of micro- and nanoparticles by various technologies and from a wide variety of materials (including biodegradable polymers and hybrid materials), as well as the surface modification of polymers and polymer particles by wet-chemistry, to introduce tailor-made properties

Miles A. Miller Assistant Professor in the Department of Radiology at Harvard Medical School and Principal Investigator in the Center for Systems Biology at Massachusetts General Hospital

He serves as a member of the Developmental Therapeutics program at the Dana Farber / Harvard Cancer Center, and is a faculty of the Harvard Medical School Bioinformatics and Integrative Genomics PhD Program.

CONFIRMED DISCUSSION LEADERS

Twan Lammers Head of the Department of Nanomedicine & Theranostics, at the Institute for Experimental Molecular Imaging (ExMI), at RWTH Aachen University Clinic

Twan Lammers is professor of medicine at RWTH Aachen University Clinic. His work mainly focuses on image-guided drug delivery and tumor-targeted combination therapies.

Manuel Sanchez-Felix Senior Fellow, Novel Delivery Technologies Group Novartis Institutes for BioMedical Research

Dr. Manuel Sanchez-Felix is a Senior Fellow with the Chemical and Pharmaceutical Profiling (CPP) group at the Novartis Institutes for BioMedical Research in Cambridge, MA. He is a scientific leader with over 20 years of experience in drug discovery and development where he co-invented and contributed to the successful development and launch of various pharmaceutical products. At Novartis, Dr. Sanchez-Felix leads a cross-functional group from Discovery and Development that is responsible for the evaluation and implementation of external Novel Delivery Technologies.

Marianne Ashford AstraZeneca, UK

Marianne Ashford, PhD, is a Senior Principal Scientist in a global role in Advanced Drug Delivery Department within Pharmaceutical Sciences at AstraZeneca. Marianne is responsible for applying drug delivery approaches which enable the progression of innovative medicines and is working to enable novel targets through intracellular delivery of new modalities such as nucleic acid based drugs.

Giuseppe Battaglia Founding members of the he Cancer Research UK City of London

ERC Consolidator grantee and ICREA Research Professor. In 2019 GB was appointed senior group leader at the Institute of Bioengineering of Catalonia, part of the newly established Barcelona Institute of Science and Technology

Alexander N. Zelikin Professor in Medicinal Chemistry at Aarhus University (Aarhus, Denmark)

Alexander N. Zelikin is a Professor in Medicinal Chemistry at Aarhus University (Aarhus, Denmark). Before moving to Aarhus, he received a PhD in polymer chemistry from Moscow State University (2003) and held research positions at MIT (with Robert Langer), Cornell University (with David Putnam) and at the University of Melbourne (with Frank Caruso).

Andrew Lewis VP Pharmaceutical Sciences at Quotient Sciences

VP Pharmaceutical Sciences at Quotient Sciences where he leads a team of 120 scientists working on formulation development, clinical manufacturing and pharmaceutical analysis for clients’ drug product programmes.

Inma Conejos Sanchez AECC Researcher Polymer Therapeutics Laboratory - CENTRO DE INVESTIGACIÓN PRINCIPE FELIPE

Inma obtained her degree in chemistry at the University of Valencia (Spain) in July 2007 and then she joined the Polymer Therapeutics lab in Valencia (Spain), headed by Dr. María J. Vicent

Ana Armiñán Polymer Therapeutics Laboratory

Ana is co-author of 1 patent and 25 academic articles published in international renowned Journals and she is a peer reviewer of the journals “Nanomedicine: Nanotechnology, Biology, and Medicine”, “Journal of Controlled Release” and “Molecular Pharmaceutics” among others.

Michael Wagner Senior Vice President Dewpoint Therapeutics

Michael Wagner is a biotech entrepreneur. He serves currently as Senior Vice President, Chemistry and Drug Discovery, at Dewpoint Therapeutics – an US and Germany based company exploring biomolecular condensates.

Vicent J. Nebot CHIEF TECHNICAL OFFICER AT POLYPEPTIDE THERAPEUTIC SOLUTIONS

He is currently working as Chief Technical Officer at PTS in the translation of polymer-based therapeutics to clinics.

Julen Oyarzabal CSO at Columbus Venture Partners

Julen Oyarzabal has spent more than 20 years working in the drug discovery and biopharmaceutical industry.

The 13th edition of the ISPT Conference will be held at:

Signup our newsletter to get update, event or promotion.

Speakers

Discussion of the latest developments in the emerging field of Polymer Therapeutics.

PLENARY SPEAKERS

CONFIRMED INVITED SPEAKERS

CONFIRMED DISCUSSION LEADERS

Newsletter